Browsing by Autor "Rodrigo Quera"

Now showing 1 - 8 of 8

Colitis eosinofílica: una entidad aparte
(2024) Rodrigo Quera; Paulina Núñez; Christian von Mühlenbrock; José Joaquín Caerols Pérez; Luis Fernando Herbozo Contreras
Eosinophilic colitis (EoC), a rare immune-mediated disease that is part of the eosinophilic gastrointestinal diseases, is characterized by the presence of an eosinophilic infiltrate in the colonic wall in symptomatic patients.Before considering the diagnosis of EoC, other diseases associated with colonic eosinophilia should be ruled out, such as parasitic infections, drugs, chronic immune-mediated diseases, and neoplasms.The symptoms of EoC are variable and non-specific, being abdominal pain and diarrhea the most common.Although systemic corticosteroids and budesonide have demonstrated their efficacy, these drugs have only been evaluated in case series studies and clinical case reports.Herein, we discuss the clinical strategy for diagnosis, therapy selection, and follow-up of EoC.
Comment on: Safety of thiopurines in Inflammatory Bowel Diseases: Neither so good, nor so bad
(Arán Ediciones, 2026) Francisca Carvajal; Rodrigo Quera; Gonzalo Pizarro; Christian von Mühlenbrock; Paulina Núñez
In recent decades, the treatment of inflammatory bowel disease (IBD) has changed markedly. Several biological therapies and small molecules have been approved, leading to improved outcomes and quality of life of these patients. However, access to these new therapies is heterogeneous across different countries. In this scenario, the use of thiopurines, through personalized treatment, remain a valid option.
Desafíos en la adherencia a STRIDE-II: perspectivas de gastroenterólogos y pacientes con enfermedad inflamatoria intestinal
(Elsevier BV, 2025) Francisca Carvajal; Karin Herrera; Paulina Núñez; Lilian Flores; Andrea Córdova; Gonzalo Pizarro; Pamela San Martín; Rodrigo Quera
Effectiveness of Infliximab in Common Variable Immunodeficiency Associated with Enteropathy.
(Arán Ediciones, 2023) Rodrigo Quera; Paulina Núñez; Pía Zañartu; Luis Contreras
Common variable immunodeficiency (CVID) is the most common symptomatic primary immunodeficiency in adults, with non-infectious gastrointestinal involvement present in up to 50 % of patients, with the small intestine and colon being the most affected areas. Reports have evaluated the effectiveness of biologic therapy in this scenario. Here, we describe the clinical, endoscopic, and histological findings of a patient who presented a satisfactory response to infliximab.
Gastrointestinal microbiome, what is behind faecal microbiota transplantation?
(Elsevier BV, 2021) Pamela Thomson; Paulina Núñez; Rodrigo Quera; Constanza Bay
Mesalamine induced hepatotoxicity. Is mesalamine safe?
(Arán Ediciones, 2024) Javier Pérez-Valenzuela; Lorena Castro Solari; Rodrigo Quera; Luis Contreras
Mesalamine is a medication used widely in the treatment of patients with inflammatory bowel disease. Although mesalamine is considered safe, hepatotoxicity has been reported with an incidence of 0-4%. We present the clinical picture of a patient with hepatotoxicity due to mesalamine. A 79-year-old woman in the context of chronic diarrhea, a left-sided ulcerative colitis diagnosis was made, and treatment was initiated with oral mesalamine 4 g per day, and mesalamine suppositories. Before starting treatment, she had normal liver test results. After three months, she presented with headache, fatigue, and intermittent low fever. Her laboratory tests showed a liver profile with a cholestatic pattern, and elevation of inflammatory parameters. Mesalamine was suspended, and an extensive study was performed. Cholangioresonance reported intra and extrahepatic bile duct dilation without obstruction, and thickening of the intrahepatic bile duct. She progressed with worsening of the liver profile without signs of liver failure. A liver biopsy was performed, which showed chronic non-suppurative cholangitis with granulomas and focal concentric fibrosis related to medium-caliber bile ducts, and IgG4 stain was negative.
Treatment with hyperbaric oxygen in a Crohn`s disease patient
(Arán Ediciones, 2024) Paula Calderón; Rodrigo Quera; Paulina Núñez; Lilian Flores
Despite advances in the treatment of inflammatory bowel disease, particularly with biological therapies and new small molecules, a significant gap still exists in achieving persistent remission from a symptomatic, biomarker, and endoscopic perspective. In this context, hyperbaric oxygen therapy (HBOT) is considered as a therapeutic strategy. This approach has also been suggested for managing ischemic ulcers located at anastomotic sites. In this clinical case, we describe the clinical and endoscopic evolution of a challenging-to-manage Crohn's disease (CD) patient with an ischemic ulcer at the ileo-rectal anastomosis who underwent HBOT.
Vancomycin in the treatment of Inflammatory Bowel Disease: There is a role beyond Clostridioides difficile infection.
(Arán Ediciones, 2023) Paula Calderón; Oriana M. Damas; Paulina Núñez; Rodrigo Quera
The development of new biological agents and small molecules has revolutionized the treatment of Inflammatory Bowel Disease (IBD). However, many patients do not respond or gradually lose their response, necessitating the search for other therapeutic strategies (1). In this clinical case, we describe the evolution of a patient with difficult-to-manage Crohn's Disease (CD) who was treated with oral vancomycin.